| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$4,283,874 ) |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | P30HS029752 | Boston Health Equity & community-Aligned Learning Health System (Boston-HEALHS) | 000 | 2 | AHRQ | 11/18/2024 | $978,045 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R34MH137223 | Developing measures to improve access to integrated mental health care services in under-resourced global settings | 000 | 1 | NIH | 11/4/2024 | $0 |
| | 2025 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9E53185 | Transition for Youth with Autism and/or Epilepsy Demonstration Projects | 01 | 1 | HRSA | 10/16/2024 | $0 |
| | 2025 | 2023 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01CA238335 | Digital Health Supported Weight Management Intervention Delivered by Community Health Workers Among Public Housing Residents | 001 | 4 | NIH | 11/1/2024 | -$179,376 |
| | 2025 | 2023 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | UM1DA049412 | MassHEAL - Reducing overdose deaths by 40% (2019-2023) | 000 | 4 | NIH | 10/1/2024 | -$4,589,462 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH116140 | Boston University Medical Campus-Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 000 | 5 | NIH | 11/14/2024 | -$1,989 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH116140 | Boston University Medical Campus-Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 000 | 5 | NIH | 11/14/2024 | -$124,441 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01CA238335 | Digital Health Supported Weight Management Intervention Delivered by Community Health Workers Among Public Housing Residents | 000 | 3 | NIH | 11/1/2024 | -$137,636 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA046527 | Researching Effective Strategies to Prevent Opioid Death (RESPOND) | 000 | 5 | NIH | 10/1/2024 | -$93,505 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD096798 | Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women - Administrative Supplement | 001 | 5 | NIH | 10/17/2024 | -$438 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD096798 | Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women - Administrative Supplement | 000 | 5 | NIH | 10/17/2024 | -$2,231 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21DA053307 | Identifying and Testing Post-Overdose Outreach Adaptations to Enhance Survivor Engagement During the COVID-19 Pandemic | 000 | 2 | NIH | 10/16/2024 | $0 |
| | 2025 | 2022 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01MH117123 | Optimizing a Paraprofessional, Family Partner Navigation Model for Children | 000 | 5 | NIH | 10/15/2024 | -$12,463 |
| | 2025 | 2021 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21DK119740 | Role of intravascular ultrasound in Central Venous Stenosis in ESRD patients | 000 | 2 | NIH | 10/16/2024 | -$6,117 |
| | 2025 | 2021 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | P30DK046200 | Boston Nutrition Obesity Research Center | 001 | 29 | NIH | 10/10/2024 | -$8,778 |
| | 2025 | 2021 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | P30DK046200 | Boston Nutrition Obesity Research Center | 000 | 29 | NIH | 10/10/2024 | -$66,187 |
| | 2025 | 2021 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | P30DK046200 | Boston Nutrition Obesity Research Center | 002 | 29 | NIH | 10/10/2024 | -$931 |
| | 2025 | 2021 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23DA045085 | Collaborative Care Office-Based Opioid Treatment for Adolescents and Young Adults | 000 | 4 | NIH | 10/1/2024 | -$38,367 |
|
| Issue Date FY: 2024 ( Subtotal = $32,029,863 ) (Continued on the next page) |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R13DA052198 | Substance Use Modeling Consortium Workshop to Support the Public Health Response to the Overdose Crisis in North America | 001 | 4 | NIH | 7/8/2024 | $24,956 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MD019068 | Adapting an Evidence-Based Intervention to Improve the Hospital Discharge Process for Patients with Limited English Proficiency | 001 | 2 | NIH | 7/8/2024 | $161,950 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T3442136 | Primary Care Training and Enhancement-Community Prevention and Maternal Health | 00 | 4 | HRSA | 5/24/2024 | $589,916 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | UT953486 | Supporting Fetal Alcohol Spectrum Disorders (FASD) Screening and Intervention | 00 | 1 | HRSA | 9/18/2024 | $949,979 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | UT953486 | Supporting Fetal Alcohol Spectrum Disorders (FASD) Screening and Intervention | 01 | 1 | HRSA | 9/23/2024 | $0 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32AI052074 | BU Clinical HIV/AIDS Research Training Program (BU-CHART | 000 | 19 | NIH | 6/3/2024 | $542,752 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9746074 | Special Projects of National Significance - Demonstration/Implementation Sites | 01 | 3 | HRSA | 9/17/2024 | $74,999 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9746074 | Special Projects of National Significance - Demonstration/Implementation Sites | 00 | 3 | HRSA | 7/2/2024 | $299,993 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HS028814 | Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections | 000 | 3 | AHRQ | 5/9/2024 | $487,417 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 00 | 2 | HRSA | 3/15/2024 | $147,368 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D3349076 | Preventive Medicine Residency | 01 | 2 | HRSA | 5/30/2024 | $247,386 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133940 | New Therapeutic Leads for Proteinuric Kidney Diseases | 000 | 3 | NIH | 5/9/2024 | $256,320 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 004 | 3 | NIH | 5/17/2024 | $24,827 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA055488 | Persistent HIV-1 expression and microglia dysfunction | 000 | 4 | NIH | 5/17/2024 | $739,881 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA054268 | MOUD Comparative Effectiveness Study | 000 | 4 | NIH | 5/1/2024 | $542,395 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9E53185 | Transition for Youth with Autism and/or Epilepsy Demonstration Projects | 00 | 1 | HRSA | 7/5/2024 | $449,795 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 000 | 1 | NIH | 4/1/2024 | $833,881 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R61DA059856 | Substance Use Prevention for Recently displaced Adults (SUPRA) | 001 | 1 | NIH | 4/3/2024 | $0 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 001 | 1 | NIH | 4/1/2024 | $0 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R61DA059856 | Substance Use Prevention for Recently displaced Adults (SUPRA) | 000 | 1 | NIH | 3/28/2024 | $779,967 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 003 | 3 | NIH | 3/13/2024 | $372,422 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL155451 | Targeting PGC-1a for the treatment of sickle cell disease | 000 | 3 | NIH | 5/10/2024 | $350,000 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA058367 | PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | 000 | 2 | NIH | 6/17/2024 | $1,209,970 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | U01DK133092 | Boston Chronic Kidney Disease Research Biopsy Center | 000 | 3 | NIH | 8/19/2024 | $799,999 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 000 | 4 | NIH | 2/21/2024 | $111,830 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 002 | 4 | NIH | 5/16/2024 | $4,970 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 001 | 4 | NIH | 5/14/2024 | $7,456 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K24AT011561 | Mentoring and Patient-Oriented Research in Mind and Body Practices | 000 | 4 | NIH | 8/16/2024 | $121,371 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA046527 | Researching Effective Strategies to Prevent Opioid Death (RESPOND) | 000 | 7 | NIH | 7/19/2024 | $866,750 |
| | 2024 | 2024 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R34DA058124 | Sustaining recovery for people on opioid agonist treatment with conversational agents | 001 | 2 | NIH | 8/9/2024 | $221,624 |
|
